Pivotal bioVenture Partners Fund I, L.P. filings

This page lists the SEC filings reported by Pivotal bioVenture Partners Fund I, L.P..

SEC filings by Pivotal bioVenture Partners Fund I, L.P. (ownership)
Type	Filed	Filer	Subject	Shares Owned	Percent Owned
SC 13D/A	2024-02-12	Pivotal bioVenture Partners Fund I, L.P.	Inozyme Pharma, Inc.	2,923,110	4.7%	EDGAR
SC 13D/A	2024-02-12	Pivotal bioVenture Partners Fund I, L.P.	Rallybio Corp	2,404,644	6.4%	EDGAR
SC 13D/A	2024-02-12	Pivotal bioVenture Partners Fund I, L.P.	Bolt Biotherapeutics, Inc.	3,058,419	8.1%	EDGAR
SC 13G/A	2024-02-12	Pivotal bioVenture Partners Fund I, L.P.	Oculis Holding AG	2,414,972	7.4%	EDGAR
SC 13D/A	2023-08-08	Pivotal bioVenture Partners Fund I, L.P.	Inozyme Pharma, Inc.	2,923,110	6.2%	EDGAR
SC 13D/A	2023-05-23	Pivotal bioVenture Partners Fund I, L.P.	Inozyme Pharma, Inc.	2,804,062	6.4%	EDGAR
SC 13D/A	2023-04-04	Pivotal bioVenture Partners Fund I, L.P.	Inozyme Pharma, Inc.	2,740,072	6.3%	EDGAR
SC 13G	2023-03-15	Pivotal bioVenture Partners Fund I, L.P.	Oculis Holding AG	3,032,296	9.3%	EDGAR
SC 13G/A	2022-08-25	Pivotal bioVenture Partners Fund I, L.P.	Akouos, Inc.	1,794,088	4.9%	EDGAR
SC 13D	2022-04-28	Pivotal bioVenture Partners Fund I, L.P.	Inozyme Pharma, Inc.	2,661,154	6.6%	EDGAR
SC 13G/A	2022-02-14	Pivotal bioVenture Partners Fund I, L.P.	Akouos, Inc.	1,794,088	5.2%	EDGAR
SC 13G/A	2022-02-14	Pivotal bioVenture Partners Fund I, L.P.	Inozyme Pharma, Inc.	1,591,154	6.7%	EDGAR
SC 13D/A	2021-08-13	Pivotal bioVenture Partners Fund I, L.P.	Bolt Biotherapeutics, Inc.	3,058,419	8.4%	EDGAR
SC 13D	2021-08-12	Pivotal bioVenture Partners Fund I, L.P.	Rallybio Corp	2,271,311	7.3%	EDGAR
SC 13D	2021-02-17	Pivotal bioVenture Partners Fund I, L.P.	Bolt Biotherapeutics, Inc.	1,891,467	5.5%	EDGAR
SC 13G/A	2021-02-09	Pivotal bioVenture Partners Fund I, L.P.	Iterum Therapeutics plc	945,085	1.2%	EDGAR
SC 13G	2021-02-09	Pivotal bioVenture Partners Fund I, L.P.	Akouos, Inc.	1,794,088	5.2%	EDGAR
SC 13G	2021-02-09	Pivotal bioVenture Partners Fund I, L.P.	Inozyme Pharma, Inc.	1,591,154	6.8%	EDGAR
SC 13D	2020-08-04	Pivotal bioVenture Partners Fund I, L.P.	Inozyme Pharma, Inc.	1,591,154	7.1%	EDGAR
SC 13D	2020-07-10	Pivotal bioVenture Partners Fund I, L.P.	Akouos, Inc.	1,794,088	5.5%	EDGAR

Form 13F-HR: The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
Form SC 13D/G: Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
Form 3, 4, and 5: Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.